On the public citation graph

Population pharmacokinetic and exposure–response analysis for trastuzumab administered using a subcutaneous “manual syringe” injection or intravenously in women with HER2-positive early breast cancer

https://doi.org/10.1007/s00280-015-2922-5
0 signed · 99 inferred · view as graph

Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.

Is this your work? Sign in with ORCID and put your name on the claims that are yours.
Claim with ORCID
Reference health. See whether every reference in this work resolves to a known work and none has been retracted — and get a dated CiteStamped badge you can embed.
See reference health

What this work says

Outgoing claims: the papers this work cites, builds on, or argues with.

inferredcites →https://doi.org/10.1007/bf01061469openalex-snapshot
Building population pharmacokineticpharmacodynamic models. I. Models for covariate effects
inferredcites →https://doi.org/10.1007/s00280-005-1026-zopenalex-snapshot
Population pharmacokinetics of trastuzumab in patients With HER2+ metastatic breast cancer
inferredcites →https://doi.org/10.1016/j.canlet.2005.01.041openalex-snapshot
Herceptin: mechanisms of action and resistance
inferredcites →https://doi.org/10.1016/s1470-2045(12)70329-7openalex-snapshot
Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I–III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial
inferredcites →https://doi.org/10.1038/psp.2013.63openalex-snapshot
Use of a Population Pharmacokinetic Approach for the Clinical Development of a Fixed‐Dose Subcutaneous Formulation of Trastuzumab
inferredcites →https://doi.org/10.1038/sj.onc.1202526openalex-snapshot
Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers
inferredcites →https://doi.org/10.1055/s-0032-1321831openalex-snapshot
Development of a Subcutaneous Formulation for Trastuzumab - Nonclinical and Clinical Bridging Approach to the Approved Intravenous Dosing Regimen
inferredcites →https://doi.org/10.1055/s-0033-1357211openalex-snapshot
Development of a Subcutaneous Formulation for Trastuzumab – Nonclinical and Clinical Bridging Approach to the Approved Intravenous Dosing Regimen
inferredcites →https://doi.org/10.1093/annonc/mdu524openalex-snapshot
Subcutaneous versus intravenous formulation of trastuzumab for HER2-positive early breast cancer: updated results from the phase III HannaH study
inferredcites →https://doi.org/10.1111/j.1476-5381.2009.00190.xopenalex-snapshot
Therapeutic antibodies: successes, limitations and hopes for the future
inferredcites →https://doi.org/10.1177/0091270012436560openalex-snapshot
Comparison of Subcutaneous and Intravenous Administration of Trastuzumab: A Phase I/Ib Trial in Healthy Male Volunteers and Patients With HER2‐Positive Breast Cancer
inferredcites →https://doi.org/10.1200/jco.1999.17.9.2639openalex-snapshot
Multinational Study of the Efficacy and Safety of Humanized Anti-HER2 Monoclonal Antibody in Women Who Have HER2-Overexpressing Metastatic Breast Cancer That Has Progressed After Chemotherapy for Metastatic Disease
inferredcites →https://doi.org/10.1208/s12248-009-9133-0openalex-snapshot
Importance of Shrinkage in Empirical Bayes Estimates for Diagnostics: Problems and Solutions
inferredcites →https://doi.org/10.2165/11531280-000000000-00000openalex-snapshot
Clinical Pharmacokinetics of Therapeutic Monoclonal Antibodies
inferredcites →https://doi.org/10.2165/11535960-000000000-00000openalex-snapshot
Population Pharmacokinetics of Therapeutic Monoclonal Antibodies
inferredcites →https://doi.org/10.5414/cpp48297openalex-snapshot
Serum albumin concentration: a predictive factor of infliximab pharmacokinetics and clinical response in patients with ulcerative colitis

What points at this work

Incoming claims: where this work appears in other papers’ reference lists and arguments.

inferred← citeshttps://doi.org/10.2139/ssrn.4113877openalex-extracted
inferred← citeshttps://doi.org/10.1002/ange.202005124openalex-snapshot
Harnessing Effective Molarity to Design an Electrochemical DNA‐based Platform for Clinically Relevant Antibody Detection
inferred← citeshttps://doi.org/10.1002/anie.202005124openalex-snapshot
Harnessing Effective Molarity to Design an Electrochemical DNA‐based Platform for Clinically Relevant Antibody Detection
inferred← citeshttps://doi.org/10.1002/cpt.3133openalex-snapshot
Challenging the Norm: A Multidisciplinary Perspective on Intravenous to Subcutaneous Bridging Strategies for Biologics
inferred← citeshttps://doi.org/10.1002/jcph.1362openalex-snapshot
Development of a Subcutaneous Fixed‐Dose Combination of Pertuzumab and Trastuzumab: Results From the Phase Ib Dose‐Finding Study
inferred← citeshttps://doi.org/10.1002/jcph.1771openalex-snapshot
Exposure‐Response and Population Pharmacokinetic Analyses of a Novel Subcutaneous Formulation of Daratumumab Administered to Multiple Myeloma Patients
inferred← citeshttps://doi.org/10.1002/psp4.13234openalex-snapshot
A model‐based approach using GSK3772847, an anti‐interleukin‐33 receptor monoclonal antibody, as a showcase to predict SC administration PK and free target dynamics based on PK and total target measurements after IV administration
inferred← citeshttps://doi.org/10.1002/psp4.13303openalex-snapshot
Pharmacokinetics‐Based Design of Subcutaneous Controlled Release Systems for Biologics
inferred← citeshttps://doi.org/10.1007/978-3-030-80962-1_344-1openalex-snapshot
Chemotherapy-Induced Cardiotoxicity in Cancer Treatment: Mechanisms and Its Prevention
inferred← citeshttps://doi.org/10.1007/978-3-031-20298-8_24openalex-snapshot
Therapeutic Proteins and Advanced Therapy Medicinal Products
inferred← citeshttps://doi.org/10.1007/978-3-032-00775-9_344openalex-snapshot
Chemotherapy-Induced Cardiotoxicity in Cancer Treatment: Mechanisms and Its Prevention
inferred← citeshttps://doi.org/10.1007/s00018-019-03340-wopenalex-snapshot
Mechanisms and potential interventions associated with the cardiotoxicity of ErbB2-targeted drugs: Insights from in vitro, in vivo, and clinical studies in breast cancer patients
inferred← citeshttps://doi.org/10.1007/s00280-016-3099-2openalex-snapshot
Ethnic sensitivity assessment of the antibody–drug conjugate trastuzumab emtansine (T-DM1) in patients with HER2-positive locally advanced or metastatic breast cancer
inferred← citeshttps://doi.org/10.1007/s00280-018-3728-zopenalex-snapshot
Population pharmacokinetic and covariate analyses of intravenous trastuzumab (Herceptin®), a HER2-targeted monoclonal antibody, in patients with a variety of solid tumors
inferred← citeshttps://doi.org/10.1007/s00280-019-03826-1openalex-snapshot
Pharmacokinetic and exploratory exposure–response analysis of pertuzumab in patients with operable HER2-positive early breast cancer in the APHINITY study
inferred← citeshttps://doi.org/10.1007/s00280-021-04296-0openalex-snapshot
Population pharmacokinetic and exploratory exposure–response analysis of the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer in the FeDeriCa study
inferred← citeshttps://doi.org/10.1007/s00280-024-04707-yopenalex-snapshot
Pharmacokinetics of trastuzumab and its efficacy and safety in HER2-positive cancer patients
inferred← citeshttps://doi.org/10.1007/s10147-025-02935-7openalex-snapshot
The fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in Chinese patients with HER2-positive early breast cancer: primary analysis of the phase III, randomized FDChina study
inferred← citeshttps://doi.org/10.1007/s11523-019-00684-yopenalex-snapshot
Subcutaneous Trastuzumab: A Review in HER2-Positive Breast Cancer
inferred← citeshttps://doi.org/10.1007/s40259-023-00626-1openalex-snapshot
Advancing Subcutaneous Dosing Regimens for Biotherapeutics: Clinical Strategies for Expedited Market Access
inferred← citeshttps://doi.org/10.1007/s40262-018-0680-3openalex-snapshot
Influence of Antigen Mass on the Pharmacokinetics of Therapeutic Antibodies in Humans
inferred← citeshttps://doi.org/10.1007/s40262-019-00828-3openalex-snapshot
Drug Exposure to Establish Pharmacokinetic–Response Relationships in Oncology
inferred← citeshttps://doi.org/10.1016/j.aca.2025.344427openalex-snapshot
A novel approach for quantifying therapeutic monoclonal antibodies in blood through liquid chromatography–tandem mass spectrometry
inferred← citeshttps://doi.org/10.1016/j.addr.2026.115916openalex-snapshot
Pharmacokinetic modeling and quantitative prediction of subcutaneous absorption of antibody-based therapeutics – An update
inferred← citeshttps://doi.org/10.1016/j.biopha.2021.111620openalex-snapshot
The mechanistic insights of the arrhythmogenic effect of trastuzumab
inferred← citeshttps://doi.org/10.1016/j.bios.2023.115488openalex-snapshot
Enzyme - Switch sensors for therapeutic drug monitoring of immunotherapies
inferred← citeshttps://doi.org/10.1016/j.bios.2024.116988openalex-snapshot
Electrochemical methods for evaluation of therapeutic monoclonal antibodies: A review
inferred← citeshttps://doi.org/10.1016/j.breast.2021.03.003openalex-snapshot
Is weight-based IV dosing of trastuzumab preferable to SC fixed-dose in some patients? A systematic scoping review
inferred← citeshttps://doi.org/10.1016/j.critrevonc.2023.103913openalex-snapshot
Optimizing benefit/risk in oncology: Review of post-marketing dose optimization and reflections on the road ahead
inferred← citeshttps://doi.org/10.1016/j.ctrv.2025.102974openalex-snapshot
Systematic literature review of intravenous versus subcutaneous administration of oncology therapies: A clinical, economic and patient perspective
inferred← citeshttps://doi.org/10.1016/j.esmoop.2020.100007openalex-snapshot
Flexible care in breast cancer
inferred← citeshttps://doi.org/10.1016/j.ijpharm.2025.126515openalex-snapshot
Expert insights into the development of large-volume subcutaneous drugs with permeation enhancers: A survey examining challenges, alternatives, and future directions
inferred← citeshttps://doi.org/10.1016/j.jconrel.2019.10.040openalex-snapshot
Removal of interstitial hyaluronan with recombinant human hyaluronidase improves the systemic and lymphatic uptake of cetuximab in rats
inferred← citeshttps://doi.org/10.1016/j.microc.2017.05.005openalex-snapshot
A short review of the pharmacokinetic behavior of biological medicinal agents for the clinical practice
inferred← citeshttps://doi.org/10.1016/j.mtbio.2026.103052openalex-snapshot
From permeation enhancer to therapeutic enabler: Advances, applications, and translational perspectives in hyaluronidase-based drug delivery
inferred← citeshttps://doi.org/10.1016/j.pharmthera.2021.108022openalex-snapshot
Therapeutic antibodies – natural and pathological barriers and strategies to overcome them
inferred← citeshttps://doi.org/10.1016/j.talanta.2022.123842openalex-snapshot
Microporous Affinity Membranes and Their Incorporation into Microfluidic Devices for Monitoring of Therapeutic Antibodies
inferred← citeshttps://doi.org/10.1021/acssensors.0c01046openalex-snapshot
Rapid, Cost-Effective Peptide/Nucleic Acid-Based Platform for Therapeutic Antibody Monitoring in Clinical Samples
inferred← citeshttps://doi.org/10.1038/s41401-024-01397-3openalex-snapshot
A recombinant fragment antigen-binding (Fab) of trastuzumab displays low cytotoxic profile in adult human cardiomyocytes: first evidence and the key implication of FcγRIIA receptor
inferred← citeshttps://doi.org/10.1038/s41523-022-00393-2openalex-snapshot
Alternative trastuzumab dosing strategies in HER2-positive early breast cancer are associated with patient out-of-pocket savings
inferred← citeshttps://doi.org/10.1038/s41598-026-55508-7openalex-snapshot
Anti-human T lymphocyte porcine immunoglobulin attenuates experimental autoimmune encephalomyelitis by inhibiting T cell activation
inferred← citeshttps://doi.org/10.1039/d3sd00126aopenalex-snapshot
Therapeutic drug monitoring of immunotherapies with novel Affimer–NanoBiT sensor construct
inferred← citeshttps://doi.org/10.1055/s-0045-1812068openalex-snapshot
A Retrospective Multicenter Real-World Study to Determine the Efficacy and Safety of PHESGO in HER2-Positive Breast Cancer from a Community Oncology Practice in Western India
inferred← citeshttps://doi.org/10.1080/14737167.2019.1554437openalex-snapshot
Behind the subcutaneous trastuzumab hype: evaluation of benefits and their transferability to Central Eastern European countries
inferred← citeshttps://doi.org/10.1080/19420862.2019.1605270openalex-snapshot
Anin vitroFcRn- dependent transcytosis assay as a screening tool for predictive assessment of nonspecific clearance of antibody therapeutics in humans
inferred← citeshttps://doi.org/10.1080/19420862.2023.2285277openalex-snapshot
Monoclonal antibody and protein therapeutic formulations for subcutaneous delivery: high-concentration, low-volume vs. low-concentration, high-volume
inferred← citeshttps://doi.org/10.1080/19420862.2025.2512217openalex-snapshot
Does one model fit all mAbs? An evaluation of population pharmacokinetic models
inferred← citeshttps://doi.org/10.1093/eurheartj/ehag609openalex-snapshot
Quality standards for preclinical research in cardio-oncology
inferred← citeshttps://doi.org/10.1097/md.0000000000014136openalex-snapshot
Population pharmacokinetics and individualized lobaplatin regimen for the treatment of Chinese small cell lung cancer in the elderly
inferred← citeshttps://doi.org/10.1101/2024.10.03.616349openalex-snapshot
Zebrafish Avatar-test predicts patient’s tumor response to chemotherapy in breast cancer: a co-clinical study towards personalized medicine
inferred← citeshttps://doi.org/10.1111/bcp.14731openalex-snapshot
Intravenous and subcutaneous administration of trastuzumab in a patient on peritoneal dialysis
inferred← citeshttps://doi.org/10.1111/bcp.15628openalex-snapshot
Population pharmacokinetics and exposure–response analyses of daratumumab plus pomalidomide/dexamethasone in relapsed or refractory multiple myeloma
inferred← citeshttps://doi.org/10.1111/bph.70710openalex-snapshot
BeatVecNet classifies drug‐induced contractile phenotypes from beat‐gated motion vectors in micropatterned human induced pluripotent stem cell‐derived cardiomyocytes
inferred← citeshttps://doi.org/10.1111/cts.13788openalex-snapshot
Modeling the subcutaneous pharmacokinetics of antibodies co‐administered with rHuPH20
inferred← citeshttps://doi.org/10.1155/2024/9551710openalex-snapshot
Subcutaneous Trastuzumab: An Observational Study of Safety and Tolerability in Patients With Early HER2‐Positive Breast Cancer
inferred← citeshttps://doi.org/10.1158/1078-0432.c.6530562openalex-snapshot
Data from Clinical and Immunologic Responses to a B-Cell Epitope Vaccine in Patients with HER2/neu-Overexpressing Advanced Gastric Cancer—Results from Phase Ib Trial IMU.ACS.001
inferred← citeshttps://doi.org/10.1158/1078-0432.c.6530562.v1openalex-snapshot
Data from Clinical and Immunologic Responses to a B-Cell Epitope Vaccine in Patients with HER2/neu-Overexpressing Advanced Gastric Cancer—Results from Phase Ib Trial IMU.ACS.001
inferred← citeshttps://doi.org/10.1158/1078-0432.ccr-20-3742openalex-snapshot
Clinical and Immunologic Responses to a B-Cell Epitope Vaccine in Patients with HER2/neu-Overexpressing Advanced Gastric Cancer—Results from Phase Ib Trial IMU.ACS.001
inferred← citeshttps://doi.org/10.1158/1078-0432.ccr-23-1683openalex-snapshot
Antibody Drug Clearance: An Underexplored Marker of Outcomes with Checkpoint Inhibitors
inferred← citeshttps://doi.org/10.1177/1060028017715727openalex-snapshot
Influence of Anthropometric Characteristics in Patients With Her2-Positive Breast Cancer on Initial Plasma Concentrations of Trastuzumab
inferred← citeshttps://doi.org/10.1177/1060028020902318openalex-snapshot
Pharmacokinetics of Trastuzumab After Subcutaneous and Intravenous Administration in Obese Patients
inferred← citeshttps://doi.org/10.1177/10781552221137702openalex-snapshot
Pharmacokinetic characterization, benefits and barriers of subcutaneous administration of monoclonal antibodies in oncology
inferred← citeshttps://doi.org/10.1186/s12859-020-03854-2openalex-snapshot
A computational diffusion model to study antibody transport within reconstructed tumor microenvironments
inferred← citeshttps://doi.org/10.1200/go.22.00328openalex-snapshot
Efficacy, Safety, Pharmacokinetics, and Immunogenicity of DRL-Trastuzumab Versus Herceptin in Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer: A Randomized Controlled Trial
inferred← citeshttps://doi.org/10.1200/jco.2016.69.1899openalex-snapshot
How to Manage the Obese Patient With Cancer
inferred← citeshttps://doi.org/10.1200/jgo.18.00155openalex-snapshot
Is the Fixed-Dose Intravenous Trastuzumab Policy Warranted in Limited-Resource Settings?
inferred← citeshttps://doi.org/10.1208/s12248-018-0284-8openalex-snapshot
Survival Prolongation Index as a Novel Metric to Assess Anti-Tumor Activity in Xenograft Models
inferred← citeshttps://doi.org/10.1254/fpj.24022openalex-snapshot
Pharmacological properties and clinical development overview of pertuzumab (genetical recombination), trastuzumab (genetical recombination) and vorhyaluronidase alfa (genetical recombination) (PHESGO® combination for subcutaneous injection MA, IN)
inferred← citeshttps://doi.org/10.12677/acm.2026.1682977openalex-snapshot
Comparison of Subcutaneous and Intravenous Formulations in Neoadjuvant Chemotherapy Combined with Targeted Therapy for Breast Cancer
inferred← citeshttps://doi.org/10.13040/ijpsr.0975-8232.12(4).1989-00openalex-snapshot
inferred← citeshttps://doi.org/10.1515/cclm-2026-0777openalex-snapshot
Therapeutic monoclonal antibodies mimicking paraproteins in immunofixation electrophoresis: migration profiles of 21 commonly used agents
inferred← citeshttps://doi.org/10.1634/theoncologist.2018-0065openalex-snapshot
Adjuvant Subcutaneous Trastuzumab for HER2-Positive Early Breast Cancer: Subgroup Analyses of Safety and Active Medical Conditions by Body Weight in the SafeHer Phase III Study
inferred← citeshttps://doi.org/10.21037/tcr.2017.09.14openalex-snapshot
Role of pharmacokinetic modeling and simulation in precision dosing of anticancer drugs
inferred← citeshttps://doi.org/10.2147/ppa.s103156openalex-snapshot
Weight-based dosing in medication use: what should we know?
inferred← citeshttps://doi.org/10.2174/9789815223910124090006openalex-snapshot
Cardiotoxicity Caused by Doxorubicin and Trastuzumab: Current Understanding for Future Preventive Strategies
inferred← citeshttps://doi.org/10.21873/anticanres.13023openalex-snapshot
Subcutaneous Trastuzumab Combined with Pertuzumab and Docetaxel as First-line Treatment of Advanced HER2-positive Breast Cancer
inferred← citeshttps://doi.org/10.22038/ijbms.2020.44651.10432openalex-snapshot
Trastuzumab increases pulmonary vein arrhythmogenesis through modulating pulmonary vein electrical and conduction properties via phosphatidylinositol 3-kinase signaling.
inferred← citeshttps://doi.org/10.2217/imt-2020-0204openalex-snapshot
rHuPH20-Facilitated Subcutaneous Administration of Monoclonal Antibodies in Cancer Therapy
inferred← citeshttps://doi.org/10.3390/antib7010010openalex-snapshot
Factors Affecting the Pharmacology of Antibody–Drug Conjugates
inferred← citeshttps://doi.org/10.3390/antib8010003openalex-snapshot
Pharmacologic Considerations in the Disposition of Antibodies and Antibody-Drug Conjugates in Preclinical Models and in Patients
inferred← citeshttps://doi.org/10.3390/ph14050450openalex-snapshot
Simulating Costs of Intravenous Biosimilar Trastuzumab vs. Subcutaneous Reference Trastuzumab in Adjuvant HER2-Positive Breast Cancer: A Belgian Case Study
inferred← citeshttps://doi.org/10.6084/m9.figshare.13251036openalex-snapshot
Additional file 1 of A computational diffusion model to study antibody transport within reconstructed tumor microenvironments
inferred← citeshttps://doi.org/10.70675/3d1cacc8z0fc2z48d0zb4eczd34fea6551dcopenalex-snapshot
Pharmacocinétique et relation dose-concentration-effet du rituximab dans la polyartrite rhumatoïde et les vascularités associées aux anticorps anti-cytoplasme des neutrophiles
Editorial review for independent work. ICSAC — the Institute for Complexity Science and Advanced Computing — runs a structured editorial panel for researchers publishing outside journals, and publishes on CiteStamp rails. Submission is free and goes through ORCID: icsacinstitute.org/submit.